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The 29th annual meeting of the Society for Immunotherapy of Cancer (SITC) was held November 7-9, 2014 in National
Harbor, MD and was organized by Dr. Arthur A. Hurwitz (National Cancer Institute), Dr. Kim A. Margolin (Stanford
University), Dr. Daniel E. Speiser (Ludwig Center for Cancer Research, University of Lausanne) and Dr. Walter J. Urba
(Earle A. Chiles Research Institute, Providence Cancer Center). This meeting included over 1,600 registered participants
from 28 separate countries, making it the largest SITC meeting held to date. It highlighted significant worldwide
progress in the development and application of cancer immunology to the practice of clinical oncology, including
advances in diagnosis, prognosis and therapy, utilizing several immunological pathways and mechanisms for a variety
of oncologic conditions. Presentations and posters demonstrated that many concepts that had been pursued
preclinically in the past are now being translated into clinical practice, with clear benefits for patients.
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The 29th annual meeting of SITC took place at the
Gaylord National Hotel and Convention Center. It was an
exciting meeting marked by a number of extraordinary
achievements in the field of tumor immunology and im-
munotherapy. The gathering came in the wake of great
news about major progress in clinical cancer immunother-
apy, with promising results of anti-PD1 and anti-PD-L1
therapy in advanced melanoma and further solid tumors.
Dr. Finn gave a keynote lecture entitled: “Prophylactic
Cancer Vaccines - Feasibility and Progress”. Dr. Trinchieri
of the National Cancer Institute received the 2014 Richard
V. Smalley, MD Memorial Award for his outstanding re-
search and achievements in cancer therapy. As part of the
award, he gave a keynote address entitled, “Cancer as a
Disease of the Metaorganism.” In this report, we
summarize the sessions of the meeting. Slides from many
presentations are available on the SITC website for meet-
ing attendees and SITC members.* Correspondence: walter.urba@providence.org
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William Merritt (National Cancer Institute) gave a grant
funding update and discussed current and pending Pro-
gram Announcements as well as updating NCI-held im-
mune modifiers and the NCI Experimental Therapeutics
Clinical Trials Network (ETCTN). The total appropri-
ation to NCI has remained fairly constant since 2009
while the number of research project grants (RPGs) de-
clined following a peak in 2008 (5,472) to 4,816 in 2013.
The success rate for RPGs has declined from 23.6% in
2004 to 13.6% in 2013. Just about all grants in the top
9% were funded, some between the 9th and 15th percen-
tiles, and a few grants between the 15th and 25th percen-
tiles were funded by “Exception”. Dr. Merritt indicated
that no significant changes are expected in the current
fiscal year (FY15).
A new opportunity to collaborate with NIH scientists
and the clinical center was presented. Opportunities for
research on “Metabolic Reprogramming to Improve Im-
munotherapy”, “Pathway to Independence Awards in
Cancer Research”, and the “Transition Career Develop-
ment Award” were described. Dr. Merritt also an-
nounced the upcoming PAs/RFAs for “Assay Validation
for High Quality Markers for NCI-supported Clinicall. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vocative Questions RFA is planned for Spring 2015. The
new NIH Genomic Data Sharing policy was also
described.
The inventory of NIH-held immune modifiers was de-
scribed with an emphasis on IL-15, IL-7, IL-12, and anti-
PD-1 (both nivolumab and pembrolizumab). The con-
tacts for investigators interested in obtaining these
agents for clinical trial can be found in the slide deck on
the SITC website. These and other checkpoint blockade
inhibitors may also be available for protocol develop-
ment in the ETCTN, whose objectives were discussed by
Dr. Merritt. The major theme is to encourage Team Sci-
ence and collaborations between the extramural and
intramural communities. The major goals are as follows:
1) Research and development for new treatments; 2)
Tumor characterization in biomarker-driven studies; 3)
Enhanced understanding of cancer biology; and 4) Edu-
cation and training for young investigators.
FDA update
Raj Puri (U.S. Food and Drug Administration) gave an
update on FDA regulatory policy related to cancer im-
munotherapy. The respective offices within FDA respon-
sible for different oncology products (small-molecules,
biologics, cellular and gene therapies, vaccines, etc) were
reviewed. The oncology product approvals by the CBER
Office of Cellular, Tissue and Gene Therapies (OCTGT)
were listed as follows; 1) antigen-presenting cells pulsed
with GM-CSF-PAP in androgen-resistant prostate cancer
(sipuleucel-T); 2) intravesical therapy for bladder cancer;
and 3) hematopoietic progenitor cell therapy using cord
blood. Citations and links were given for several recent
“Guidance for Industry” documents relevant to immuno-
therapy including preclinical assessment of investiga-
tional cellular and gene therapy products and trial
design for studies of virus or bacteria-based gene therapy
and oncolytic products. Also discussed were workshops
on standards for cellular therapy and regenerative medi-
cine, innovations in breast cancer drug development and
courses to train clinical investigators. Breakthrough ther-
apy designation was also discussed. Dr. Puri reported
that at the time of the meeting, approximately 30 such
requests had been granted. Links to FDA websites, docu-
ments and contact information can be obtained from
the slides, which are archived on the SITC website.
Richard V. Smalley, MD memorial award
In 2014, Giorgio Trinchieri was the recipient of the
Richard V. Smalley, MD Memorial Award. The Award
is given in memory of Dr. Smalley, who was a past
President and Charter member of SITC. Dr. Trinchieri
(National Cancer Institute, National Institutes of
Health) has made seminal contributions to ourunderstanding of innate resistance to cancer and mo-
lecular mechanisms of immune cell activation. Dr.
Trinchieri delivered a seminar on his recent, ground-
breaking work identifying a role for the regulation of
tumor immunity by the commensal microbiota. The
talk was entitled, “Cancer as a Disease of the
Metaorganism”.
Among their initial findings was that depletion of the
intestinal microbiota by treatment of tumor-bearing
mice with a cocktail of antibiotics reduced the efficacy of
an immune-based therapy, which delivered intra-
tumoral blockade of IL-10 in combination with the
TLR9 agonist, CpG oligodeoxynucleotides. Similar re-
sults were also noted using classical platinum-based che-
motherapeutics. A role for pro-inflammatory cytokines
like TNF and IL-12 were demonstrated for the immune-
based therapies, whereas in the chemotherapy model, a
strong role for reactive oxygen species was reported,
which was associated with NOX2-expressing myeloid
cells. These reactive oxygen species mediated DNA ad-
duct formation induced by the platinum-based com-
pounds. While the precise mechanism by which the
biome primes myeloid cells is unclear, a role for biome
diversity in generating “systemic inflammatory tone” was
suggested. The composition of the biome was related to
the overall production of TNF and particular species can
have positive or negative influences. Oral administration
of LPS restored the anti-tumor response in antibiotic-
treated animals. While platinum-based compounds re-
quired MyD88, the precise receptor-ligand pair remains
unknown. Not surprisingly, IFN-based signature path-
ways also played a critical role in the biome-driven anti-
tumor responses. In closing, Dr. Trinchieri shared two
images: a nicely maintained park and a forest fire. He
used them to suggest that the on-going war against can-
cer be thought of as a careful system of “park manage-
ment”, rather than the historical “slash-and-burn
approaches”. Clearly, by understanding the complexity
of the interaction between the microbiota and immune
system, the human metaorganism, as Dr. Trinchieri la-
beled it, can be manipulated to generate more potent
anti-tumor immunity.
Inflammation, innate immunity, and microbiome
Following the Smalley Award lecture, a symposium enti-
tled “Inflammation, Innate Immunity, and Microbiome”
was held. The first speaker was session Co-Chair William
J. Murphy from the University of California. Dr. Murphy
spoke on the vast and complex biology of NK cells. Dr.
Murphy addressed the role of NK cell regulation by cyto-
kines like TGF-β and regulatory T cells. Understanding
this process is critical as NK cells contribute to tumori-
genesis at multiple stages. Similar to tumor immunity, the
anti-viral response is controlled by NK cells. In turn, NK
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that bind to MHC on target cells. This is critical for tumor
immunity, as many cancer types down-regulate MHC as
an immune evasion strategy, which might make them
more susceptible to NK cells. In the mouse, these recep-
tors are marked by Ly49 allotypes. Dr. Murphy provided
data demonstrating that in a murine CMV model, particu-
lar subsets of Ly49-licensed NK cells were critical for
maintaining anti-viral immunity. In the non-transplant
setting of leukemia, licensed NK cells did not play a crit-
ical role in survival of the host. In contrast, with
hematopoietic stem cell transfer, unlicensed NK cells were
important for improved survival, with a response compar-
able to Treg cell depletion. Given the predominance of
early NK cell repopulation after stem cell transfer, under-
standing the mechanisms by which NK cells contribute to
engraftment and tumor control will undoubtedly improve
cancer therapies and transplant survival.
Session Co-Chair Marco Colonna (Washington Uni-
versity School of Medicine) presented his laboratory’s
work on innate lymphoid cells (ILCs). This compart-
ment is comprised of at least 3 known subsets (ILC1,
2, and 3) that have unique functional and phenotypic
characteristics, which he likened to helper T cell sub-
sets. ILC3 are NKp44 + CD56 + cells, which are found
in multiple tissues. Like Th17 cells, they make IL-22,
which triggers antimicrobial peptide synthesis and
chemokine expression. These cells were shown to be
dependent on the expression of the aryl hydrocarbon
receptor for development, and in their absence, mice
have altered development of intestinal lymphoid tis-
sues that made them more susceptible to bacterial in-
fections (for example, C. rodentium) and resistant to
inflammatory bowel disease. ILC1 are NKp44 + CD103+
cells which are elevated in Crohn’s disease and display a
TGF-β expression signature. While they share some
similarities with NK cells, ILC1 seem to be a divergent
cell population with unique function and expression pat-
tern. Dr. Colonna finished by sharing some comparative
genetic profiling studies using the ImmGen database.
Varied expression profiles enabled comparison of ILC to
NK cells in the intestinal tissues and ILC2 to
alternatively-activated macrophages. Overall, these stud-
ies provided a novel perspective on a unique class of
cells that provide critical support to innate immune
responses.
Two short talks were selected for presentation from
the submitted abstracts. In the first, Leticia Corrales
(University of Chicago) described a role for the DNA
sensor STING in eliciting anti-tumor T cell responses.
Using the B16 tumor model, Dr. Corrales reported that
synthetic STING ligands could promote regression of
these established transplantable melanomas, with similar
results in other tumor models. In the second talk, AyeletSivan (University of Chicago) described a role for the
microbiome in tumor growth. Different colonies of mice
were shown to have different tumor growth kinetics, as-
sociated with different T cell activation profiles. Interest-
ingly, fecal transfer from the mice, which support tumor
immunity to the mice with faster tumor growth resulted
in increased T cell frequencies and slower tumor growth.
Ms. Sivan postulated that this may be due to effects on
the antigen presenting cell populations. These findings
are consistent with those presented by Dr. Trinchieri
and should lend themselves to important advances in
eliciting tumor immunity.
The final presentation of the session entitled “The role
of the intestinal microbiome in GVHD”, was delivered
by Marcel van den Brink (Memorial Sloan Kettering
Cancer Center). Studies on the role of the microbiota af-
fecting bone marrow failure date back to the 1970’s.
Treatment of patients with antibiotics has been observed
to improve bone marrow graft acceptance and reduce
GVHD, with a similar effect demonstrated in experimen-
tal murine models. Conversely, development of GVHD
was shown to be associated with a focused intestinal
microbiome; poor outcome in bone marrow transplant-
ation was associated with reduced diversity of intestinal
flora. Protection from GVHD was associated with the
presence of high levels of the genus Blautia, a Gram-
positive anaerobic bacterium, with a strong predictive
power. Antibiotics reduced the presence of Blautia in pa-
tients, as did reduced caloric intake. Further studies
demonstrated that in a murine model of GVHD, intro-
duction of Blautia improved survival. From a mechanis-
tic standpoint, bacterial production of short chain fatty
acids such as butyrate and propionate improved GVHD
outcome. Options for dietary manipulation to increase
fatty acid levels were proposed to improve bone marrow
transplantation survival. Similarly, antibiotics that spare
Blautia were demonstrated to have similar effects. The
findings reported by Dr. van den Brink supported the
concept that complex interactions between the micro-
biome and the immune response influence cancer and
immune reconstitution. In this case, it appears that the
biome components (contributed by Blautia) promote an
immune suppressive environment that reduces GVHD
and improves survival.
Lung cancer: immunology and immunotherapy
In the past few years, advances in immunotherapy have
transformed our approach to lung cancer treatment. It is
now clear that PD-1 immune checkpoint blockade may
substantially help lung cancer patients, and there is a
new sense of hope in the field. Because lung cancer is
the leading cause of cancer deaths worldwide, the sheer
numbers of patients who may benefit from these agents
has, in turn, transformed the field of immunotherapy
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boutique therapy for a few selected patient groups. The
session on lung cancer included reviews of the recent
advances in clinical development of PD-1/PD-L1 tar-
geted therapies, as well as ongoing work in vaccine ther-
apy and manipulating the tumor microenvironment.
Laurence Zitvogel (Institute Gustave Roussy) described
the use of autologous dendritic cell-derived exosomes
(Dex), loaded with desired peptides, as a cell-free vaccine
strategy to enhance NK cell and T cell anti-tumor im-
mune responses. She presented data from a phase II trial
testing metronomic cyclophosphamide followed by Dex,
pulsed with MAGE-1, MAGE-3, NY-ESO-1, and MART-
1 peptides, as maintenance immunotherapy in HLA-A2
positive patients with advanced NSCLC after disease
control with cisplatin-based chemotherapy. In 22 treated
patients, the median overall survival was 15 months and
time to progression 4 months. While there was minimal
induction of antigen-specific T cell or antibody re-
sponses, an increase in NKp30 mediated function, mea-
sured by TNF-α release, was observed in patients after 4
Dex vaccines and correlated with overall survival. This
evidence of immune activity supports further investiga-
tion of Dex, perhaps in combination with PD-1 immune
checkpoint blockade or other immunomodulatory strat-
egies, ultimately taking into account the molecular char-
acteristics of different subsets of lung cancer and
defining biomarkers of immune response and resistance.
Roy Herbst (Yale Cancer Center) reviewed the key
findings and challenges to date of PD-1/PD-L1-based
immunotherapy in NSCLC. A comparison of the re-
ported data from 5 different anti-PD-1/anti-PD-L1
agents revealed a consistency in response rates at ap-
proximately 20% in unselected NSCLC patients. How-
ever, this does not capture the true clinical benefit of
these agents. The unique patterns of clinical responses
to immune checkpoint blockade, including the pro-
longed durability of many responses, and the pattern of
pseudoprogression seen in 10-15% patients, demon-
strates a clear need to establish more reliable endpoints
for evaluating the benefits of immunotherapy than
standard tumor measurements such as the RECIST sys-
tem. One proposed option is to create a measure of ag-
gregate clinical activity that reflects median duration of
response or to use 1-year or 2-year landmarks to capture
the long-term benefit of these agents, including pro-
longed stability or minor regressions. It remains unclear
whether any of the structural design differences in the
PD-1 and PD-L1 antibodies (with variations in binding
affinity, targets, antibody isotype and ADCC potential)
will be critical to identify the agent(s) among many
current contenders that possesses the optimal thera-
peutic index, which is likely to be different depending on
tumor type and characteristics of the immune tumormicroenvironment. Antibodies targeting PD-L1 instead
of PD-1 may decrease toxicity because this allows PD-L2
to retain its role in protection against autoimmunity—a
concept supported by the observation of fewer events of
severe pneumonitis among anti-PD-L1 agents to date;
Dr. Herbst cautioned against drawing premature conclu-
sions, since these drugs arrived later, when the clinic was
more prepared to handle new immune toxicities, and
the outcomes are not fully available yet.
John Nemunaitis (Mary Crowley Medical Research
Center) presented phase 2b results from the TIME study
of TG4010 immunotherapy combined with first line
chemotherapy in patients with advanced NSCLC.
TG4010 is a modified vaccinia vector encoding the en-
tire tumor antigen MUC1 and interleukin-2. Retrospect-
ive subgroup analysis of earlier phase 1 data suggested a
survival advantage from the addition of TG4010 to
chemotherapy in patients with a normal level of circulat-
ing activated NK cells (CD16+ CD56+ CD69+) but not
in patients with a high level. This led to the design of a
prospective study, using Bayesian analysis that incorpo-
rates the earlier results, to enroll patients with advanced
MUC1-expressing NSCLC to receive TG4010 versus pla-
cebo with first line platin-based chemotherapy. On sub-
group analysis of 221 patients, those with a normal level
of pre-treatment activated NK cells (n = 170) and the pa-
tients with nonsquamous histology (n = 195) demon-
strated a statistically significant improvement in PFS with
a trend towards OS benefit. The PFS benefit was greatest
in patients designated with both a low level of activated
NK cells and nonsquamous histology (n = 152) at 5.9 ver-
sus 4.9 months for the TF4010 versus placebo arm, re-
spectively. The vaccine was well tolerated, and a large
phase III registrational trial is now underway to confirm
and further quantitate the activity of the vaccine in com-
bination with chemotherapy.
Julie Brahmer (Sidney Kimmel Comprehensive Cancer
Center) reviewed recent efforts to determine biomarkers
and characteristics of response to PD-1 immune check-
point blockade in NSCLC patients. To date, only two
markers have been found to correlate with higher re-
sponse rates: PD-L1 expression and smoking status.
However, neither is reliable in guiding which patients
should be treated with these agents as there are many pa-
tients whose tumors are PD-L1 negative or are never-
smokers who respond to PD-1 blockade as well. The limi-
tations of PD-L1 status include heterogeneity of PD-L1 ex-
pression between primary site and metastasis, between
metastatic sites of the same tumor, and among cells of the
tumor microenvironment. Further, interpretation of these
data may be confounded by the induction of PD-L1 expres-
sion by the secreted products of local tumor-infiltrating
lymphocytes, which is an important determinant of its
role as a therapeutic target. In addition, the varying
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demic and industry groups continues to be problematic,
because different antibodies and staining conditions are
used, with variations in designation of “positive” or
“negative” results. For example, the threshold for “PD-L1
positive” is arbitrarily set at 1% by some studies and at
5% by others. Both Dr. Brahmer and Dr. Herbst spoke in
favor of standardizing this and further parameters of the
assessment of PD-L1 expression. Former and current
smokers have higher response rates to PD-1 checkpoint
blockade than never-smokers, which is likely due to the
increased number of mutations in tumors that result
from long-term tobacco exposure. Other clinical charac-
teristics that have been examined but not shown to cor-
relate with response include age, sex, performance
status, and even histology, despite earlier evidence sug-
gesting the squamous cell histology would have a higher
response rate. Biomarkers that failed to show a correl-
ation include tumor-infiltrating lymphocytes, PD-L2 ex-
pression, CD4: CD8 ratio, lymphoid aggregates, and
necrosis. Dr. Brahmer also commented on future com-
binatorial strategies to increase the response rates to PD-
1 therapy by turning non-inflamed, PD-L1 negative tu-
mors into immune-responsive tumors, through the use
of radiation, molecularly targeted therapy, tumor-based
vaccines, T cell therapy, and epigenetic priming. It is
likely that the optimal strategies for enhancing the out-
come of PD-1-directed therapies for lung cancer will dif-
fer from those for other tumor histologies.
Mikael Pittet (Harvard University) described work
by his group and others examining the role of tumor-
associated macrophages (TAMs) that may promote
tumor growth. The density of TAM correlates with de-
creased survival in various cancer types, including
NSCLC. Overproduction of angiotensin II (AngII) in a
lung cancer mouse model (KP mice) increased
hematopoietic stem cells, which increased monocyte
precursors to TAMs. Tumors were shown to produce
angiotensinogen (Agt), which is a necessary precursor
of AngII. Blocking AngII signaling in KP mice with
enalapril, an angiotensin-converting-enzyme inhibitor
(ACE inhibitor; a drug that is frequently used to treat
hypertension), led to a decrease in TAMs, a decrease
in tumor growth, and increased survival. These find-
ings are intriguing in light of two retrospective studies
that showed improved outcomes in NSCLC patients
who were on an ACE inhibitor for treatment of their
hypertension [1,2]. These results support a promising
new therapeutic direction for targeting tumor-immune
cell interactions that may impact on anti-tumor im-
mune responses. A number of other strategies to
characterize and manipulate tumor-associated macro-
phages are ongoing and likely to complement other
therapeutic modalities.Tumor microenvironment and immunosuppression
A session entitled “Tumor Microenvironment and
Immunosuppression” delivered 3 diverse plenary talks
and one shorter talk, all describing immune regulatory
mechanisms related to the tumor microenvironment. In
the first presentation, Suzanne Ostrand-Rosenberg
(University of Maryland, Baltimore County) described a
novel signaling pathway for the PD-1/PD-L1 axis. In
addition to PD-1, CD80 is a second PD-L1 ligand. The
binding affinity of CD80:PD-L1 is comparable to
CD80:CD28 and PD-1:PD-L1 binding. Tumors that
were transduced to express CD80 had reduced PD-
1:PD-L1 binding and provided improved T cell priming
in vitro. A soluble form of CD80 provided similar bene-
fits: increased costimulation of T cells in vitro and im-
proved immunity to tumor challenge. Taken together,
these findings suggest that providing soluble forms of
CD80, either alone or in combination with other immu-
nomodulatory therapies, may be more effective than
antibodies directed against PD-1 or PD-L1.
In the second presentation, Gabriel Rabinovich (Insti-
tuto de Biologia y Medicina Experimental (IByME)) de-
scribed the role of Galectins in promoting immune
suppression. Galectins are a family of highly conserved
secreted lectins, which bind N-acetyl-lactosamine and
contribute to protein sorting and turnover. Galectin
levels in tumors associate with tumor progression and
metastasis, and blocking Galectin-1 promotes T cell-
mediated tumor regression. Galectin-1 also promotes
immune suppression, in part through regulatory T cells
and tolerogenic dendritic cells and their secreted cyto-
kines. Ligands that bind Galectin-1 include glycans and
VEGFR2, which are induced by hypoxia on tumor cells
and endothelial cells through an NF-κB-dependent
process. As such, Galectin-1 binds VEGFR2 and induces
angiogenesis; studies reported by Dr. Rabinovich suggest
that reducing Galectin-1 levels can improve VEGFR-
targeted therapies. Results were presented in multiple
primary and transplantable tumor models, which dem-
onstrated the utility of a Galectin-1 antibody at targeting
tumor vasculature and enhancing tumor regression
through immune-mediated mechanisms. These studies
demonstrate that Galectin-1 may serve as a critical regu-
lator of tumor progression. Given the multitude of li-
gands, directly targeting this unique receptor may
provide a powerful way to inhibit tumor progression and
improve immunity to tumor antigens, either alone or in
combination with other immune-based therapies.
The third plenary lecture of the session was delivered
by Weiping Zou (University of Michigan) on the com-
plexity and balance of immunity within the tumor
microenvironment. Dr. Zou summarized the role of PD-
L1 in inducing suppressive signals in the tumor micro-
environment. The impact of this pathway was related to
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ficacy of PD-1 blockade. The role of both regulatory T
cells and suppressive myeloid cells was also discussed.
Specifically, the link between myeloid-derived suppressor
cells (MDSCs) and ovarian cancer was presented. Inter-
estingly, MDSCs were also suggested to support (ovar-
ian) cancer cell stemness. This was associated with
MDSC-induced expression of micro RNA (miR)101. A
more detailed mechanism was presented, which impli-
cated the transcriptional repressor CtBP2 which regu-
lates expression of the stem cell-associated genes OCT3/
4, SOX2, and Nanog. Additional work was presented on
a novel role for IL-22 in promoting stemness of colorec-
tal cancer. Those studies reported that CD4+ T cells that
secrete IL-22 (Th22 cells) accelerated cancer growth in a
human tumor xenograft model as well as a tumor spher-
oid culture model. IL-22 was associated with increased
expression of stem cell-associated genes and Histone
H3K70 dimethylation, a marker of gene activation; this
was confirmed by association of H3K79 binding to simi-
lar stem cell-associated gene promoters, which was
STAT3-dependent. A correlation between elevated
H3K79 levels and poor outcome in colorectal cancer
supported these findings. Dr. Zou presented a novel, “3
signal” model for carcinogenesis which integrates genetic
modifications, inflammatory signals that impact stem-
ness, and immune suppressive signals that regulate host
defense. These findings underscore the critical relation-
ship between diverse inflammatory responses and car-
cinogenesis and the need to understand further these
complexities.
This session also contained a short talk that was se-
lected from the submitted abstracts. Emanuela Romano
(University of Lausanne) described a mechanism by
which anti-CTLA-4 (ipilimumab) promotes anti-tumor
T cell responses. Interestingly, patients with the highest
clinical responses to ipilimumab treatment were shown
to have elevated levels of circulating CD11c+CD16bright
monocytes at baseline. These cells were demonstrated to
mediate ADCC of regulatory T cells in vitro in presence
of ipilimumab. The data presented by Dr. Romano also
suggested that ipilimumab responders had increased in-
filtration of tumors by CD16+ macrophages compared to
non-responders, correlating with fewer tumor-associated
Treg cells. These findings are consistent with previously
reported data using experimental murine models and
will therefore provide guidance for other checkpoint
molecule-targeted therapies.
Immunopotentiation by radiotherapy: mechanisms and
opportunities
Jennifer Jones (NIH/NCI Vaccine Branch) presented
data on the identification of optimal immunotherapy tar-
gets for use with radiation therapy for metastatic tumorsin preclinical models. The data presented demonstrate
that TIM-1 costimulates iNKT cells and showed synergy
with radiation therapy in controlling growth of the meta-
static murine 4T1 breast tumor. A new method, nano-
FACS, was described for identification and characterization
of extracellular vesicle (EV) subsets including exosomes
(30-120 nm) and microparticles (80-800 nm) from tumor
and immune cells. This new technique has broad applic-
ability for the study of radiation effects on the tumor micro-
environment with single exosome/ microparticle analysis
providing a window into the dynamic changes occurring in
the tumor immune microenvironment. Proof of concept
data were presented validating the fidelity of sorting of EV,
with the ability to purify and assess the biological activity of
EV from the blood of mice treated with radiation and
immunotherapy.
Sandra Demaria (New York University) discussed the
role of radiation-induced TGF-β activation as an inhibi-
tor of both dendritic cell activation and T cell effector
function. TGF-β blockade using an anti-TGF-β antibody
(1D11) in two preclinical breast cancer models resulted
in a synergistic benefit when combined with local tumor
irradiation (RT), with an associated increase in tumor in-
filtrating lymphocytes (TILs); and loss of therapeutic
benefit was observed following depletion of either CD4
or CD8 T cells. In addition, TGF-β blockade increased
RT-induced activation of tumor infiltrating dendritic
cells (DC), and allowed priming of tumor specific CD8
T cells against several tumor-derived peptide epitopes
following RT. Gene expression studies showed upregula-
tion of immune system activation pathway genes when
TGF-β blockade was combined with RT. These results
provided a compelling rationale for an ongoing trial of
RT with the TGF-β neutralizing antibody fresolimumab
used at two different concentrations (1 or 10 mg/kg) in
patients with metastatic breast cancer (NCTO1401062,
PI S. Formenti). Preliminary analysis demonstrated an
increase in tumor specific CD8+ T cells in some patients
during treatment. An example of an abscopal response
seen in a treated patient was shown. Prolonged overall
survival and progression-free survival in the arm receiv-
ing the higher dose of fresolimumab suggest benefit of
blocking TGF-β with radiotherapy. Furthermore, the
presence of PD-1 (on TIL), PD-L1 and PD-L2 (on tumor
and myeloid cells), suggests that the addition of PD-1
blockade to TGF-β neutralizing antibody and RT will
provide further benefit. To test this hypothesis, preclin-
ical experiments were performed in 4-T1-bearing mice
to assess the potential benefit of combining inhibition of
the PD-1 pathway with RT and TGF-β blockade.
Addition of anti-PD-1 to this combination regimen re-
sulted in significantly reduced tumor burden and in-
creased survival in mice as compared to RT and TGF-β
blockade alone. Altogether, these data demonstrate the
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multiple immunotherapies as an in situ tumor vaccine
strategy.
Simon Dovedi (University of Manchester) reported re-
sults from colorectal, breast and melanoma syngeneic
tumor models demonstrating that fractionated radiation
therapy (fRT) consisting of 5 fractions of 2 Gy resulted
in significant upregulation of tumor cell expression of
PD-L1 in vivo. Cellular depletion studies revealed that
RT-mediated increase in tumor cell PD-L1 was
dependent on CD8+ T cells. Additional data, showed
that adaptive upregulation of tumor PD-L1 following
fRT is mediated by tumor infiltrating CD8+ T cells pro-
ducing IFN-γ, and that this adaptive response is re-
stricted to the irradiated tumor site. These results
support the hypothesis that this adaptive resistance
mechanism protects tumor cells from immune-mediated
killing, and explains, at least in part, why RT alone may
not generate systemic tumor antigen-specific responses.
Treatment with either anti-PD-1 or anti-PD-L1 antibody
in combination with fRT improved mouse survival com-
pared to either treatment alone. Abscopal responses
were observed, with up to 60% of mice having a
complete response to the combination therapy. These
mice were also protected against tumor rechallenge by
the generation of long-term immunological memory.
Importantly, scheduling of administration of the anti-
PD-L1 antibody relative to the fRT was important, with
the best results obtained when anti-PD-L1 was started
(administered 3 time/wk at 10 mg/kg) on day 1 of the
fRT. Efficacy of this combined regimen was CD8+ T
cell-dependent. These results demonstrate the potential
for enhancing the efficacy of fRT through blockade of
the PD-1/PD-L1 axis.
David Roberts (CCR, NIH) discussed the role of CD47
signaling on the relative radiosensitivity of tumors and
normal tissues. Binding of CD47 to its ligand,
thrombospondin-1, affects a number of pathways includ-
ing Signal Regulatory Protein α (SIRP α) and immune
modulation. Data was presented demonstrating that
CD47 blockade using an antisense morpholino protected
bone marrow in mice treated with both local and total
body irradiation. This radioprotection is mediated by
protective autophagy, which is a CD47-mediated stress
resistance response. In contrast, CD47 blockade in mel-
anoma and fibrosarcoma syngeneic murine tumor
models enhanced RT-induced tumor growth delay
(TGD), with this effect being dependent upon CD8+ T
cells. There was also synergy between CD47 blockade,
adoptive CD8 T cell immunotherapy and RT. While
CD47 signaling limits T cell activation, CD47 blockade
increases CD8 cytotoxic T lymphocyte (CTL) activity,
and in combination with RT enhances granzyme B ex-
pression. Furthermore, elimination of CD47 in thetumor microenvironment increased RT-associated TGD.
Importantly, in human melanomas, there is an inverse
relationship between the level of CD47 expression and
the number of CD8+ infiltrating T cells, suggesting that
these results may be clinically relevant. The differential
effect of CD47 blockade in tumor vs. stromal and nor-
mal cells provides an opportunity to increase the thera-
peutic index of radiation therapy, both alone and in
combination with immunotherapy. This is based on data
showing that in normal tissues, CD47 blockade increases
cell survival via nitric oxide and VEGF signaling, en-
hanced autophagy, and induction of c-Myc and other
stem cell factors. In contrast, in tumor cells, CD47 in-
creases tumor cell death by decreasing protective au-
tophagy, inducing resistance to c-Myc regulation,
decreasing resistance to innate immunity and enhancing
CTL tumor cell killing. In addition, the results presented
demonstrate that CD47 is an immune checkpoint inhibi-
tor for T cells, and that blocking CD47 in combination
with RT enhances antitumor immunity by directly
stimulating CD8+ cytotoxic T cells, with the potential to
increase curative responses.
Immunotherapy biomarkers task force update
Lisa Butterfield (University of Pittsburgh) spoke on be-
half of the Task Force. She described the history and
background of the formation of the Task Force and the
creation of the following four working groups: 1) Im-
mune monitoring assay standardization and validation-
update; 2) New developments in biomarker assays and
technologies; 3) Assessing immune regulation and
modulation systematically (high throughput approaches);
and 4) Baseline immunity, tumor immune environment
and outcome prediction. The Task Force met at the
SITC 2014 meeting and plans were made for a one-day
meeting at NIH in 2015, an Immune biomarkers-based
SITC Guest Society Symposium at AAI 2015, and for a
manuscript describing new state-of-the-art recommen-
dations for publication in JITC in 2015.
Update: the CITN
The Cancer Immunotherapy Trials Network (CITN)
continued its success at the mission of making promis-
ing experimental agents available to the academic re-
search community, through partnership with the NCI
and Industry. Founded in 2011, the CITN experienced
growth in 2014, expanding as an NCI-supported consor-
tium from 29 to 32 universities and cancer centers in
North America. Bringing together premier cancer im-
munologists and centers under the direction of PI
Martin (Mac) Cheever (Fred Hutchinson Cancer Re-
search Center), the CITN aims to design and conduct
early phase trials for patients with cancer, to provide the
infrastructure essential for collaboration, and to gain
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testing. Anti-TIM-3, anti-TNF-alpha, and anti-IL1R were
among the recommended additions to the top-ranking
agents in 2014. As of the end of 2014, five of the top ten
agents were successfully integrated into CITN clinical
trials: Pembrolizumab (anti‐PD1) for Merkel cell cancer
and Mycosis Fungoides, agonistic anti‐CD40 with neo-
adjuvant chemotherapy for pancreatic cancer, IL15 and
an immunoconjugate of IL15 with its receptor for NK
and CD8 expansion in several solid tumors, IL7 with
sipuleucel-T for prostate cancer and as an immunomod-
ulator following adjuvant chemotherapy for older pa-
tients with breast or colon cancer, and an inhibitor of
indoleamine dioxygenase for ovarian cancer or with a
multipeptide vaccine for advanced melanoma (Figure 1).
Three priority agents (agonistic anti‐OX‐40, anti‐LAG,
and agonistic anti‐CD137) are currently not available but
likely to be in 2015, and two agents of interest (IL-12,
anti‐TGF-β) are no longer manufactured. Anticipated ac-
crual exceeds 200 patients over ten trials of seven
agents, and most of the trials have opened recently,
promising a large percentage of accrual over the next
year. Each trial is designed to test a critical clinical ques-
tion and to deliver a large dataset of immunologic corre-
lates that will elucidate mechanisms of action and
resistance that will inform future trials, most likely com-
bination strategies. In addition to the above-listed agents
in trial, the CITN has recently opened an adjuvant trial
for melanoma using the dendritic cell-targeting antibody
DEC-205 conjugated to NY-ESO-1 antigen in combin-
ation with the Toll receptor 3 agonist polyIC:LC with or
without FLT3L for dendritic cell expansion. PreliminaryFigure 1 Ranked priority immunotherapy agents: 2007 vs. 2013 and availabresults of the Phase I dose escalation trial of IL-15 were
presented at the meeting, establishing safety and im-
munologic activity and highlighting significant expansion
of natural killer cells in circulation [3]. Looking forward,
in 2015 the CITN aims to expand to fifteen trials of the
priority agents and to focus on investigating the etiology
of and potential to reverse resistance pathways to im-
munotherapy with planned amendments to the ongoing
anti-PD1 clinical trials in Mycosis Fungoides and Merkel
Cell Carcinoma. By incorporating serial biopsies and
“rescue” radiation therapy in patients not optimally
responding to PD-1 blockade, the CITN will begin to ad-
dress the ability of radiotherapy to overcome resistance
and induce a response in lesions separate from the radi-
ated site(s) of progression and to better understand the
mechanisms and requirements for radiotherapy-induced
immune responses (detailed elsewhere in this summary).
Saturday keynote address
The second Keynote presentation, entitled, “Prophylactic
Cancer Vaccines - Feasibility and Progress”, was deliv-
ered by Olivera Finn, (University of Pittsburgh). Dr. Finn
set the foundation for the talk by describing the public
health problems of cancer management, the need for
more effective preventive therapies, and the benefits of
using prophylactic immunotherapy approaches. Dr.
Finn’s success in this arena dates back to 1993, when her
first trial of a MUC-1 vaccine was conducted in patients
with breast, colon, or pancreatic cancers. In many can-
cerous tissues, MUC-1 expression loses its polarization
and MUC-1 has altered glycosylation. Targeting the
hypoglycosylated form was tested using variousility.
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measured by disease stabilization or delayed time to pro-
gression). More recently, Dr. Finn’s group has tried to
optimize the vaccine and target therapy to “intermedi-
ate” stage patients: those with adenoma at the time of
detection. An intradermal vaccine showed a 50% re-
sponse rate as measured by MUC-1-specific IgG, T cell
responses, and increased levels of MUC-1-specifc mem-
ory T cells. A Phase II trial is currently underway to de-
termine vaccine efficacy. It will enroll ~120 patients at
13 centers and have a follow-up time of up to 5 years.
Future studies may enroll cancers of diverse types. An
effort is underway to understand the reasons why up to
50% of vaccinated patients do not exhibit a detectable
response. One clue may come from the observation that
these patients have higher levels of circulating cells that
resemble MDSCs. However, no association with age,
gender, race, prior viral infections, and HLA haplotype
was noted. Moving forward, future studies will also
examine the feasibility of MUC-1 serving as an immune
target for a variety of diseases and cancer types. By
studying the biology and genetics of immune responses
to MUC-1, a highly conserved cancer antigen, more ef-
fective prophylactic vaccines can be developed.
Vaccines session
The session on vaccines provided extended insight into
the scientific challenges of vaccine development. Hans-
Georg Rammensee (University of Tübingen) gave an
overview on the “HLA-ligandome”, as it can be identi-
fied with mass-spectrometry based approaches to inter-
rogate human tumors. Interestingly, this ligandome is
largely different from the transcriptome, with only rare
peptides detected in common, probably because gene
products have considerably different RNA handling and
processing. Not surprisingly, the isolated peptides differ
in copy numbers, and this appears to be related to the
likelihood of T cell responses. Current and future inves-
tigations will clarify how often one can find mutated an-
tigens, relative to the non-mutated antigens that have
already been characterized in large numbers.
Craig Slingluff (University of Virginia) and his team
are performing multiple clinical vaccination trials in
melanoma patients, with the aim to perform side-by-side
comparisons of different antigens and adjuvants in a
stepwise vaccine development. This group has shown
clinical responses in patients who generated strong CD4
+ T cell responses to vaccination with tumor antigens. In
different studies, T cell responses were readily induced
despite mixing as many as 12 peptides in the vaccine
formulation, showing that potential competition between
peptides does not preclude proper T cell triggering. The
use of IFA was beneficial for obtaining T cell responses,
as opposed to GM-CSF. Careful studies of the vaccine-site microenvironment (VSME) showed induction of
chemokines, and T-bet and Gata3 in T cells. Vaccination
with the adjuvant AS15, containing CpG oligonucleo-
tides, induced a higher and more favorable Tbet/Gata3
ratio in the VSME.
Jill Slansky (University of Colorado) described the
identification of epitopes and related mimotopes in
breast cancer. Among tumor-antigen specific TILs, the
more frequent TCRs recognized mimotopes that were pref-
erentially associated with anti-tumor immunity, underlining
the great interest of molecular characterization of those
TCRs. For this, the group used a novel “Emulsion RT-PCR”
enabling the combined identification of TCR alpha- and
beta-chains. This technique revealed frequent sharing of
TCRs between patients, further supporting the concept that
naturally occurring TCRs may guide the choice of optimal
antigens for immunotherapy.
Gosse Adema (Radboud University Medical Center)
presented novel strategies of TME reprogramming, by
focusing on gangliosides or sialic acids. The latter dom-
inate the sugars in tumors (in contrast to healthy tissues)
and are thus attractive therapy targets. Indeed, inhibitors
of sialyl transferases show promising results in preclin-
ical models.
Daniel Speiser (Ludwig Center for Cancer Research of
the University of Lausanne) provided an overview on the
current progress and challenges in T cell vaccination.
Particular emphasis was given to TCR affinity and T cell
avidity, which can be favorably promoted by vaccinations
with low antigen doses and long intervals (at least 4
weeks) between booster vaccinations. Next generation
vaccines (“NGVs”) will likely arise progressively by com-
bining antigens with innate immune stimulators, which
need to be tested in small clinical trials for their capabil-
ities to induce T cell responses with high level correlates
of protection. These are: 1) high numbers of multifunc-
tional T cells (despite the use of low antigen doses), 2)
high avidity T cells, 3) multi-clonality, 4) migration to
tumors, 5) broad targeting of multiple tumor antigens,
and 6) long-term activity and persistence of responding
T cells.
Late-breaking abstract sessions
Four abstracts were selected for oral presentation in two
late-breaking abstract sessions. In the first session, Jennifer
Sims (Columbia University) shared her work on TCR rep-
ertoires in brain cancer. Using next-generation sequencing
of TCR, Dr. Sims reported a unique clonality among
tumor-infiltrating T cells in glioblastoma multiforme
(GBM) patients as compared to peripheral blood T cells.
She also presented data correlating TCR genotypes with
gene expression signatures of immune suppression,
leukocyte recruitment, and stress responses. In addition,
GBM patients treated with anti-CCL2 had reduced TCR
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indicator of response to therapy and serve as a “metric”
for determining individual therapies.
The second talk was delivered by Nina Bhardwaj (Mt.
Sinai School of Medicine), who spoke on activation of
DCs by matrix metalloproteinase (MMP) 2. Treatment
of DCs ex vivo resulted in increased expression of
OX40L and TNF as well as cleavage of the type I IFN re-
ceptor. Activation by MMP2 was TLR2 dependent, and
a physical association between MMP2 and TLR2 was
demonstrated. MMP2 was also associated with a TH2 re-
sponse following antigen sensitization. In the context of
tumors, Dr. Bhardwaj suggested that MMP2 expression
may promote immune evasion through supporting type
2 responses.
In the second late-breaking abstract session, Laurent
Humeau (Inovio Pharmaceuticals) presented work on a
clinical trial employing a DNA-based HPV vaccine for
treatment of cervical cancer. Patients (~150) enrolled in
the trial had grade 2/3 or 3 cervical intraepithelial neo-
plasia (CIN), and received 3 doses of an experimental
HPV16/18 vaccine delivered by intradermal or intramus-
cular electroporation. Regression of disease (to CIN1)
and HPV clearance was reported to be greater in pa-
tients who received the vaccine. Additional analysis of
immune parameters was described as underway. The
promising results were suggested to be enabling add-
itional vaccine trials.
Finally, Amy Moran (Earle A. Chiles Research Insti-
tute) talked about “OX40 agonist immunotherapy ex-
pands tumor reactive CD8 T cells and synergizes with
PD-L1 blockade to promote tumor regression”. Using
Nur77 expression as a surrogate marker for TCR affinity
(signal strength), Dr. Moran shared data using an experi-
mental tumor model, which demonstrated that both
OX40 agonist and CTLA-4 blockade resulted in Nur77hi
T cells infiltrating tumors. OX40 ligation also synergized
with blockade of the PD-1 axis, which generated a more
robust memory cell population. These findings indicate
an effective synergistic therapy, and reveal some import-
ant mechanistic insights on how OX40 ligation can pro-
mote more durable tumor immunity.
Oral poster sessions
In the first session, Jieqing Chen (MD Anderson Cancer
Center) reported on predictive immune biomarker sig-
natures in the TME of melanoma metastases associated
with TIL therapy. With a novel iterative biomarker ana-
lysis, a nine-gene gene expression signature was deter-
mined by nanostring. Lactoferrin (LTF) was found to be
overexpressed in tumors of patients that responded fa-
vorably to TIL therapy. In turn, overexpression of
IRAK1 (an inflammation driver triggering NF-kB) was
found in tumors of non-responders, advocating for usingexisting and new drugs that block IRAK1. Wenqian
Wang (University of Pittsburgh) reported that depletion
of HMGB1 in DCs suppressed tumorigenesis and pro-
moted viral clearance. In a mouse model of DC-specific
HMGB1 deletion, they showed significantly improved
immunity against vaccinia virus and pancreatic cancer
using state-of-the-art imaging technologies. Antonia
Mueller (University Hospital Zurich) and Holbrook
Kohrt (Stanford Cancer Institute) showed synergistic
anti-lymphoma activity of rituximab with 4-1BB and
PD-1 blockade that can be considered as promising se-
quential treatments. Similar approaches may also be ap-
plied in breast cancer (targeting HER-2) or head and
neck cancer (targeting EGFR). Marcin Kowanetz
(Genentech) presented data demonstrating circulating
and tumor-based biomarkers associated with responses
in cancer patients treated with anti-PD-L1 mAb. Besides
PD-L1 expression in tumors, responses were associated
with high effector T cells and IFN-γ signatures. In blood,
IL-18, ITAC, and CD8 + Ki67 + HLADR+ cells were as-
sociated with clinical responses. Claire Vanpouille-Box
(New York University School of Medicine) presented
their work entitled “Fractionated but not single-dose ra-
diation releases key signals of in situ tumor vaccination”.
They suggested that fractionated radiation therapy
mimics viral infection, with induction of type I IFN,
leading to DC mobilization. Such studies are critical for
the rational design of clinical trials exploring combin-
ation of radiotherapy with immunotherapy.
In the second oral poster session, Rikke Andersen
(Herlev Hospital) et al. summarized interesting results
of treating melanoma patients with expanded autologous
TILs. They pursued an approach with intermediate
doses of IL-2 allowing most patients to be maintained
on the intended IL-2 dose. The clinical results are favor-
able, confirming that TIL therapy continues to be highly
promising, and serves as an excellent basis for future re-
finement of adoptive cell therapy (ACT). Sonia Guedan
(University of Pennsylvania) et al. reported the effects of
signaling cassettes introduced into CARs (chimeric anti-
gen receptors). In a carefully designed mouse model,
they tested combinations of CAR transduced CD4 and
CD8 T cells with regard to their capacities to fight tu-
mors. Their results provide important clues for optimal
design of next generation CARs for clinical use. Amanda
Harper (The Ohio State University) et al. used a mouse
model to demonstrate that MICA expression on mono-
cytes can enhance NK cell responses via NKG2D, lead-
ing to enhanced response against antibody-coated tumor
targets. Priti Hegde (Genentech) et al. examined re-
sponses of bladder cancer patients to anti-PD-L1 treat-
ment and observed that enhanced expression of PD-L1
at baseline was favorable; whereas, abundance of mye-
loid cells and associated cytokines, particularly Il-1B,
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Lance Miller (Wake Forest School of Medicine) et al.
performed extended gene profiling of tumor samples
from breast cancer patients, and defined prognostic sig-
natures distinguishing different qualities of tumor micro-
environments. This approach allows the screening of
dominant molecular pathways, and may be combined
with imaging techniques. Finally, Laura Carter (Lycera)
et al. introduced novel RORγ agonists and their potency
for favorable modification of T cell polarization, promot-
ing Th17 and Tc17 cells, as opposed to Tregs. This ap-
proach was suggested to be tested in the clinic soon.
Presidential session
Numerous factors play a role in the development of an
effective antitumor response. This year’s presidential ses-
sion included presentations that examined important
mechanisms by which the production of an effective
anti-tumor response can be inhibited. The contributions
of myeloid-derived suppressor cells and β-catenin signaling
were examined. The role of another coinhibitory receptor
TIGIT (T cell immunoglobulin and immunoreceptor
tyrosine-based inhibitory motif [ITIM]) was reported. The
introduction of CD19-specific modified chimeric antigen
receptor (CAR) T cells to treat patients with refractory B-
cell malignancies has been a great success. However, trans-
lation of this strategy to an effective therapy for solid tu-
mors remains challenging. A study was presented
describing the development of a humanized anti-EGFR
variant III chimeric antigen receptor, its introduction into T
cells, and its preclinical validation, and the initiation of a
phase I clinical trial.
A number of attempts have been made to reduce
MDSC-induced suppression in tumor-bearing hosts,
with only limited impact. Paul Thevenot (Louisiana State
University) reasoned that identifying and inhibiting the
mediators of MDSC regulatory activity would help over-
come T-cell suppression and increase the efficacy of T-
cell based immunotherapy of cancer. They attempted to
determine whether stress sensor C/EBP-homologous-
stress-related protein (CHOP), a downstream product of
the integrated stress response, was a master regulator of
MDSC-suppressive activity. The ablation of CHOP al-
tered the function of MDSC, decreased their suppressive
activity, which allowed the accumulation of CD8 T cells
with antitumor activity and impaired C/EBPβ activity
and led to a reduced production of the suppressive me-
diators IL-6 and ARG-1. CHOP was proposed to be a
potential target to inhibit MDSC suppressive activity in
solid tumors.
Stefanie Spranger (University of Chicago) explored the
mechanisms by which tumors are able to prevent infil-
tration by T cells. Using molecular profiling, they dem-
onstrated that half of tumors that lack a T-cell signatureexhibit alterations in the Wnt/β-catenin signaling path-
way. Using an autochthonous mouse model of melan-
oma (inducible BRAF V600E and PTEN deletion) that
was also capable of inducible expression of β-catenin,
they showed that T-cell infiltrates were universally ab-
sent in tumors that expressed β-catenin. Tumors with
no β-catenin expression contained infiltrates of T cells,
albeit with exhausted phenotypes, that responded to com-
bined therapy with anti-CTLA-4 and anti-PD-1. Tumors
that expressed β-catenin did not develop T-cell infiltrates
and did not respond to combination immunotherapy, un-
less a deficiency of tumor-infiltrating DCs was corrected by
intratumoral injection of FLT3-ligand-derived dendritic
cells. The explanation for this difference was proposed to
be the lack of production of the chemokines CCL4 and
CXCL1 by β-catenin-deficient tumor cells.
Sema Kurtulus (Brigham and Women’s Hospital) pre-
sented data showing that TIGIT expression is increased
on CD8 T cells and Tregs in tumor tissue. TGIT is a co-
inhibitory molecule whose ligation leads to increased
IL10 production and decreased IL12 production by DCs,
and inhibition of T-cell proliferation and cytokine pro-
duction. In their murine model, TIGIT marked a subset
of Tim-3+ PD-1+ CD8+ T cells that were most dysfunc-
tional. B16 melanoma and CD38 colon carcinoma cells
grew slower in TIGIT-deficient mice. CD8 T cells from
these mice proliferated better and produced more gran-
zyme B but their transfer to wild type tumor-bearing
mice did not decrease tumor growth. However, if Tregs
were TGIT deficient, the antitumor response was en-
hanced upon transfer of CD8 T cells. Thus, TIGIT ap-
pears to suppress antitumor immune responses by
inhibiting CD8 T cells. The blockade of TIGIT appears
to slow tumor growth modestly but maximal decreases
in tumor growth were demonstrated when it was com-
bined with TIM-3 blockade. Together, TIGIT appears to
be another immune checkpoint to consider in combined
immunotherapy approaches for cancer.
Marcela Maus (University of Pennsylvania) reported
on the development of a humanized chimeric antigen re-
ceptor (CAR) that recognizes the variant III mutation of
the epidermal growth factor receptor (EGFRvIII). EGFR-
vIII, which has an in-frame deletion of a portion of the
extracellular domain that produces a neoantigen, is
found in a number of different malignancies, particularly
glioblastoma multiforme. They selected a single chain Fv
specific for the mutant EGFRvIII peptide and incorpo-
rated it into a second generation CAR T cell that in-
cludes the 4-1BB costimulatory and T-cell receptor zeta
chain signaling domains. T cells transduced with the
CART-EGFRvIII killed antigen-bearing targets, and pro-
liferated and produced cytokines specifically to EGFR-
vIII. There was no cross-reactivity with wild type EGFR
in vitro. In vivo, CART - EGFRvIII failed to recognize
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whereas cetuximab-based CAR T cells reacted both to
normal skin and EGFRvIII. The authors demonstration
that CAR T cells could control tumor growth in xeno-
geneic subcutaneous and orthotopic models of human
EGFRvIII positive glioblastoma led to the initiation of a
phase I trial in which patients with EGFRvIII+ glioblast-
omas will receive CART-EGFRvIII alone or in combin-
ation with temozolomide after surgery.
Immunoscore update
Bernard A. Fox (Earle A. Chiles Research Institute)
opened the session with the bold statement that “the im-
mune system is the ‘agent’ that improves outcome and
CURES people with metastatic cancer”. Citing the his-
torical efficacy of IL-2 and the appearance of long-term
responders after treatment, first with anti-CTLA-4 and
now with anti-PD-1, there is growing evidence to sup-
port this concept. Nevertheless, the majority of patients
with solid tumors do not experience long-term remis-
sions following immunotherapy. Based on work done by
Jerome Galon and colleagues in patients with colon can-
cer, which suggested that type, density and location of
immune cells within the tumor may be more predictive
of clinical outcome than standard TNM staging, the
SITC Immunoscore Task Force was established [4]. The
goals of the Task Force are to validate the immunoscore
as a prognostic biomarker, and if appropriate, to modify
the relevant AJCC TNM classification. These approaches
will likely lead to significant progress in the histopatho-
logial assessement of malignant disease, including the
quantification of immune cell infiltrates. Dr. Fox men-
tioned the members of the steering committee and de-
scribed the preliminary work to engage centers
throughout the world in this important initiative. As of
November 2014, control slides have been stained and
imaged. Ongoing work includes uploading images and
adopting methods for analyzing images and determining
appropriate cut-off values and performing statistical ana-
lysis. The choice of markers for the immunoscore panel
will evolve as new data arise. The constantly improving
technology allows for analysis of multiple markers,
thereby complicating the analysis but broadening the po-
tential value of this approach. The work needs to have
substantial bioinformatics infrastructure. The SITC web-
site has the slides showing the impressive analysis that is
now possible using this strategy.
Coinhibition and costimulation: targets and strategies
Brendan Curti (Earle A. Chiles Research Institute)
started the session entitled “Coinhibition and Costimula-
tion: target and strategies”. He shared clinical data con-
cerning a phase I trial using a mouse anti-OX40
antibody as an immune-stimulatory agent in late stagecancer patients. OX40 is a TNF receptor family member
expressed on CD8 T cells, and more strongly on both
conventional CD4 T cells and T regulatory CD4 T cells.
Expression of its ligand (OX40L) is only transient on
antigen presenting cells (APCs). OX40 agonistic anti-
body was shown to costimulate CD4 T cells to increase
memory development of Th1 and Th2 T cells. The treat-
ment had low to mild toxicity and with only one treat-
ment cycle, a third of the patients showed some degree
of tumor regression in at least one metastatic lesion.
Binding of the antibody was confirmed on CD8 and on
CD4 T cells, following the pattern of expression of
OX40 on these cells. This binding correlated with in-
creased proliferation of CD4 T cells, CD8 T cells and
NK cells. Stabilization of the disease in some patients
was associated with proliferation of conventional CD4
and CD8 T cells expressing the activation markers HLA-
DR and CD38. Furthermore, when these cells were
tested against autologous tumor, cells from 2 out of 3
patients responded by producing increased levels of
IFN-γ. Another phase I protocol using a Fc-OX40L fu-
sion molecule was opened in September 2014 following
these encouraging results. Dr. Curti also proposed to use
OX40 stimulation in combination with checkpoint in-
hibitors, costimulatory antibodies, or radiation therapy.
Kavita Dhodapkar (Yale University) presented a study
comparing transcriptomic data of T cells and monocytic
cells obtained from patients before and after treatment
with anti-CTLA4 or anti-PD-1 alone or in combination.
She showed that the transcriptomic changes observed
after anti-PD-1 treatment were associated with a NK cell
signature, with an increased level of granzyme B expres-
sion. Interestingly, the changes observed after anti-
CTLA4 treatment were different, with a strong associ-
ation with proliferation, and in particular an increase in
Ki67 expression. The combination of both antibodies
had a synergistic effect on T cells with increased gran-
zyme B and Ki67 expression, as well as production of
IFN-γ and IL-2 within TILs and PBMCs.
Ines Pires da Silva (NYU Cancer Center) presented
data associating NK cell exhaustion with melanoma pro-
gression. NK cells from PBMCs of melanoma patients
showed decreased capacity to produce IFN-γ and to pro-
liferate. This correlated with an increased expression of
Tim-3 on NK cells. Blocking of Tim-3 with an antibody
restored IFN-γ production and proliferation of NK cells
coming from patients.
As last speaker of the session, Robert Vonderheide
(University of Pennsylvania) presented pre-clinical and
clinical data concerning the use of the agonistic anti-
CD40 antibody in cancer immunotherapy. CD40 is a
critical regulator of the adaptive and innate immune sys-
tems, playing a central role in the licensing of dendritic
cells for stimulating antigen-specific T cells. In a mouse
Hurwitz et al. Journal for ImmunoTherapy of Cancer  (2015) 3:17 Page 13 of 14model of pancreatic adenocarcinoma, he showed previ-
ously published data demonstrating that combination of
anti-CD40 antibody together with chemotherapy could
induce tumor regression mediated by macrophages.
Addition of checkpoint inhibitors further increased
tumor regression. In patients suffering from advanced
pancreatic ductal adenocarcinoma, a phase I study using
similar treatment showed mild toxicity and some tumor
responses. In one melanoma patient that received anti-
CD40 treatment and experienced 9 year-complete remis-
sion, a drastic change in the TCR repertoire of T cells
was found, highlighting that anti-CD40 treatment can
also affect T cell development. In conclusion, anti-CD40
treatment is a suitable candidate for neoadjuvant therapy
for pancreatic cancers, with manageable toxicity and
good results.
Adoptive immunotherapy
In the “adoptive immunotherapy” session, Patrick Hwu
(University of Texas, MD Anderson Cancer Center)
showed that failure to respond to checkpoint inhibition
therapy was not indicative of a bad response to adoptive
cell therapy (ACT), as 29% of the non-responders to
checkpoint blockade therapy had a measurable response
to ACT. A detailed comparison was performed of sam-
ples from patients that have successfully undergone
ACT with TIL (representing 44% of the patients) with
the ones for whom this therapy was not successful. A
nanostring study using paraffin samples showed a correl-
ation between the high expression of T cell activation
markers (including “checkpoint” inhibitory receptors) to
a favorable outcome after ACT. To further increase
ACT efficiency, Dr. Hwu proposed to combine TIL ther-
apy with the use of BRAF inhibitors, as it was shown
that BRAF inhibition enhances T cell infiltration of
metastatic melanoma lesions. Another possible combin-
ation is the use of PI3K inhibitors. In many tumor types,
PTEN loss induces increased PI3K signaling. Dr. Hwu
showed that these tumors are more resistant to T cell in-
filtration, associated with decreased patient survival. Fur-
thermore, he found that when the PI3K pathway is more
active in a patient’s tumor, there is less chance that TILs
are prone to be expanded in vitro. High PI3K signaling
in vivo was also associated with poor cytolytic function.
One possible mechanism could be the intra-tumoral
downregulation of the autophagy pathway. Finally, he
also suggested a possible combination of ACT/PI3K in-
hibitor with PD-1 blockade.
Per thor Straten (Centre for Cancer Immune Therapy
Copenhagen) summarized the results obtained after
ACT in melanoma patients in his center. They obtained
a 20% complete response rate in 31 patients despite a
lower dose of IL-2 during the treatment, with a remark-
able 92% success rate for establishing TIL cultures.Taking advantage of these TILs, they attempted to de-
cipher the epitope specificity of T cells using 145 tetra-
mers synthesized with known MHC class I cancer
epitopes, mostly non-mutated ones. The total of all these
epitopes only represented a low percentage among the
cultured TILs, indicating that most of the recognized
epitopes in these cultures remain undefined.
Eric Tran (NIH/NCI) presented the results obtained
for ACT in advanced cholangiocarcinoma, showing poor
efficiency for inducing clinical responses. However, the
study of one case suggested that highly enriched TILs
recognizing a mutated epitope were effective at inducing
tumor regression. In an attempt to extend this investiga-
tion to other patients, Dr. Tran and colleagues systemat-
ically sequenced the genome of the tumors from each
patient to identify potential mutated epitopes recognized
by T cells. Several mutations were then incorporated to
minigenes used to transduce APCs. These APCs were
used to stimulate the patient’s TILs. On amplified cul-
tures, multiple epitopes encoded by the minigenes were
separated on several peptides used again to amplify TILs.
Reactive TIL populations were successfully expanded
from 7 out of 8 patients. These cultures will be used to
treat patients.
Another study was presented which focused on meta-
bolic switches. With the objective to enhance the capacity
of amplified TILs to treat patients, Madhusudhanan
Sukumar (NCI) studied the metabolic profile of tumor-
specific CD8+ T cells. He summarized the results from
two studies during the meeting. One concerned the switch
from oxidative phosphorylation to aerobic glycolysis, once
a T cell switches from a quiescent state to an activated
one. He showed that decreasing the glycolysis by using a
pharmacological inhibitor (2-deoxyglucose) induced “bet-
ter” differentiation of memory T cells and improved their
immunotherapeutic potential against cancer. The second
part focused on the mitochondrial status of the T cells. Dr.
Sukumar demonstrated that a low membrane potential
was associated with a much better capacity to expand
in vivo, the cells being a hematopoietic precursor like Lin-
Sca-1+ cKit + (LSK) cell or a T cell. This was associated
with the expression of the transcription factors Bcl6, Tcf7
and Klf2. The cells with a high membrane potential
showed poor capacity to expand in vivo, and associated
with high level of Eomes. One possible explanation for this
defect in expansion/survival, may be a higher level of re-
active oxygen species in the cells related to a decrease in
the transcriptional program encoding for the anti-
oxidative machinery.
The session ended with two presentations about CAR
T cells. The first one was given by Michael Jensen
(University of Washington), who presented several strat-
egies that his group developed to enhance CAR T cell ef-
ficiency, optimizing the type of cells used, the
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proposed approaches that take advantage of the integra-
tion of the mutated form of the EGFR (EGFRt) in the
construct to purify the CAR-expressing T cells and also
by potentially targeting this molecule in the patient by
using cetuximab to eliminate the CAR T cells in case of
off-target toxicity.
Michel Sadelain (Memorial Sloan Kettering Cancer
Center) presented the results of a phase I study using
the CD19-specific 19-28z CAR to treat B cell acute
lymphoblastic leukemia. Among 16 patients, the overall
complete response rate was very high (88%), with a time
to complete response averaging 24.5 days and allowing
the transition of most of these patients to a standard-of-
care allogeneic hematopoietic stem cell transplant. In
these patients, he showed that the initial tumor burden
strongly correlated with the possibility to develop severe
cytokine-release syndrome, and showed several strategies
to manage this adverse effect.
In summary, the meeting was very rich in novel results
and concepts for improving immunotherapy of cancer. It
provided ample opportunities for SITC members and
visitors to connect, communicate and enforce existing
collaborations and embark on new ones. The meeting
revealed the leading role SITC plays as an innovator in
the field, where representatives of academia and industry
meet for promoting progress in cancer research and de-
velopment of novel therapies.
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